journal
MENU ▼
Read by QxMD icon Read
search

European Heart Journal. Cardiovascular Pharmacotherapy

journal
https://read.qxmd.com/read/30715322/ivabradine-for-heart-failure-regulatory-differences-in-europe-and-united-states
#1
Thomas A Marciniak, Trygve S Hall, Dan Atar, Stefan Agewall, Victor L Serebruany
No abstract text is available yet for this article.
February 1, 2019: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30698668/angiotensin-receptor-neprilysin-inhibition-arni-for-the-treatment-of-hypertension-the-neglected-child-in-cardiovascular-pharmacotherapy
#2
Sverre E Kjeldsen, Dan Atar, Thomas von Lueder
No abstract text is available yet for this article.
January 30, 2019: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30698669/clinical-use-of-cangrelor-nationwide-experience-from-the-swedish-coronary-angiography-and-angioplasty-registry-scaar
#3
Per Grimfjärd, Bo Lagerqvist, David Erlinge, Christoph Varenhorst, Stefan James
Aims: This nationwide study aimed to analyse the first 2 years of routine clinical use of cangrelor in all Swedish patients undergoing percutaneous coronary intervention (PCI). Methods and results: This observational Swedish Coronary Angiography and Angioplasty Registry (SCAAR) study identified 915 cangrelor-treated patients. As 899 were ST-segment elevation myocardial infarction (STEMI)-patients undergoing primary PCI, we decided to exclude all non-STEMI patients (n = 16) from the following analysis...
January 28, 2019: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30689786/medical-misinformation-vet-the-message
#4
Joseph A Hill, Stefan Agewall, Adrian Baranchuk, George W Booz, Jeffrey S Borer, Paolo G Camici, Peng-Sheng Chen, Anna F Dominiczak, Çetin Erol, Cindy L Grines, Robert Gropler, Tomasz J Guzik, Markus K Heinemann, Ami E Iskandrian, Bradley P Knight, Barry London, Thomas F Lüscher, Marco Metra, Kiran Musunuru, Brahmajee K Nallamothu, Andrea Natale, Sanjeev Saksena, Michael H Picard, Sunil V Rao, Willem J Remme, Robert S Rosenson, Nancy K Sweitzer, Adam Timmis, Christiaan Vrints
No abstract text is available yet for this article.
January 28, 2019: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30689800/platelet-inhibition-with-standard-versus-lower-maintenance-dose-of-ticagrelor-early-after-myocardial-infarction-electra-a-randomized-open-label-active-controlled-pharmacodynamic-and-pharmacokinetic-study
#5
Jacek Kubica, Piotr Adamski, Katarzyna Buszko, Malwina Baranska, Joanna Sikora, Michal Piotr Marszall, Przemyslaw Sobczak, Adam Sikora, Wiktor Kuliczkowski, Tomasz Fabiszak, Aldona Kubica, Bernd Jilma, Dimitrios Alexopoulos, Eliano Pio Navarese
Aims: Currently available data indicate that reduction of ticagrelor maintenance dose (MD) 1-3 years after acute myocardial infarction (AMI) not only provides sufficient platelet inhibition, but also can improve ticagrelor's safety profile. The aim of this study was to compare the antiplatelet effect of reduced and standard ticagrelor MD in stable patients beginning one month after AMI. Methods and results: In a single-centre, randomized, open-label, active-controlled trial, on day 30 following AMI, 52 patients (26 in each study arm) were assigned in a 1:1 ratio to receive either reduced (60 mg b...
January 23, 2019: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30657876/is-p2y12-inhibitor-therapy-associated-with-an-increased-risk-of-cancer
#6
Christoph C Kaufmann, Alexander R Lyon, Johann Wojta, Kurt Huber
Antiplatelet therapy is a mainstay of cardiovascular therapy and is well established in clinical routine. Recently, the potential risk of solid cancers with P2Y12 inhibitor therapy has been an issue of growing interest. The alleged association primarily originated from the findings of an US Food and Drug Administration (FDA) review of the randomized controlled TRITON-TIMI 38 trial and the following results of the DAPT trial. The higher risk of cancer was predominately observed with the newer, more potent P2Y12 inhibitors and in the setting of prolonged dual antiplatelet therapy (DAPT)...
January 18, 2019: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30608563/adherence-to-dabigatran-etexilate-in-atrial-fibrillation-patients-intended-to-undergo-electrical-cardioversion
#7
Willemijn J Comuth, Moniek P M de Maat, Daan van de Kerkhof, Jerzy Malczynski, Steen Husted, Steen D Kristensen, Anna-Marie B Münster
Aims: Effective anticoagulation in patients undergoing electrical cardioversion (ECV) for symptomatic atrial fibrillation is important to prevent adverse events. High medication adherence is a requirement. In patients with newly diagnosed atrial fibrillation (n = 169) who were intended to undergo ECV, the aim of this study was to measure self-reported short- and long-term adherence, evaluate whether dabigatran plasma concentrations reflect adherence, measure treatment satisfaction and assess whether adherence and treatment satisfaction are correlated...
January 4, 2019: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30517633/corrigendum
#8
(no author information available yet)
No abstract text is available yet for this article.
December 5, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30500885/comparative-safety-and-effectiveness-of-dabigatran-versus-rivaroxaban-and-apixaban-in-patients-with-non-valvular-atrial-fibrillation-a-retrospective-study-from-a-large-healthcare-system
#9
Todd C Villines, Azhar Ahmad, Michaela Petrini, Wenbo Tang, Amber Evans, Toni Rush, David Thompson, Kelly Oh, Eric Schwartzman
Aims: We used the US Department of Defense Military Health System database to compare the safety and effectiveness of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (NVAF) initiating dabigatran versus rivaroxaban or apixaban. Methods and results: Two cohorts of adults with NVAF, newly initiated on standard-dose DOAC, were identified based on clinical approval dates: July 2011-June 2016 for dabigatran (150 mg BID) or rivaroxaban (20 mg QD) and January 2013-June 2016 for dabigatran (150 mg BID) or apixaban (5 mg BID)...
November 30, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30615170/old-and-new-drugs-in-cardiovascular-pharmacotherapy
#10
EDITORIAL
Stefan Agewall
No abstract text is available yet for this article.
January 1, 2019: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30496381/cabana-trial-disappointing-results
#11
LETTER
Renato De Vecchis
No abstract text is available yet for this article.
January 1, 2019: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30192930/effect-of-oral-%C3%AE-blocker-treatment-on-mortality-in-contemporary-post-myocardial-infarction-patients-a-systematic-review-and-meta-analysis
#12
Magnus Dahl Aarvik, Irene Sandven, Tatendashe B Dondo, Chris P Gale, Vidar Ruddox, John Munkhaugen, Dan Atar, Jan Erik Otterstad
Aims: Guidelines concerning β-blocker treatment following acute myocardial infarction (AMI) are based on studies undertaken before the implementation of reperfusion and secondary prevention therapies. We aimed to estimate the effect of oral β-blockers on mortality in contemporary post-AMI patients with low prevalence of heart failure and/or reduced left ventricular ejection fraction. Methods and results: A random effects model was used to synthetize results of 16 observational studies published between 1 January 2000 and 30 October 2017...
January 1, 2019: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30165588/esc-council-on-hypertension-position-document-on-the-management-of-hypertensive-emergencies
#13
Bert-Jan H van den Born, Gregory Y H Lip, Jana Brguljan-Hitij, Antoine Cremer, Julian Segura, Enrique Morales, Felix Mahfoud, Fouad Amraoui, Alexandre Persu, Thomas Kahan, Enrico Agabiti Rosei, Giovanni de Simone, Philippe Gosse, Bryan Williams
Hypertensive emergencies are those situations where very high blood pressure (BP) values are associated with acute organ damage, and therefore, require immediate, but careful, BP reduction. The type of acute organ damage is the principal determinant of: (i) the drug of choice, (ii) the target BP, and (iii) the timeframe in which BP should be lowered. Key target organs are the heart, retina, brain, kidneys, and large arteries. Patients who lack acute hypertension-mediated end organ damage do not have a hypertensive emergency and can usually be treated with oral BP-lowering agents and usually discharged after a brief period of observation...
January 1, 2019: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/29490032/heart-rate-beta-blocker-use-and-outcomes-of-heart-failure-with-reduced-ejection-fraction
#14
Nasrien E Ibrahim, Hanna K Gaggin, Alexander Turchin, Harshali K Patel, Yang Song, April Trebnick, Gheorghe Doros, Juan F Maya, Christopher P Cannon, James L Januzzi
Aims: High resting heart rate (HR ≥70 b.p.m.) is associated with worse clinical outcomes in heart failure with reduced ejection fraction (HFrEF). Heart rate, guideline-directed medical therapy (GDMT) with beta-blocker (BB), and cardiovascular outcomes were evaluated in a large integrated health network. Methods and results: Using electronic health records we examined patients with chronic HFrEF (ejection fraction ≤35%) in sinus rhythm with at least 1 year of follow-up and available serial HR and medication data between 1 January 2000 and 31 December 2014...
January 1, 2019: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30423165/outcomes-associated-with-non-recommended-dosing-of-rivaroxaban-results-from-the-xantus-study
#15
Pierre Amarenco, Sylvia Haas, Susanne Hess, Paulus Kirchhof, Marc Lambelet, Miriam Bach, Alexander Gg Turpie, A John Camm
Aims: In Europe, the approved rivaroxaban dose for stroke prevention in patients with atrial fibrillation is 20 mg once daily (od), with 15 mg od recommended in patients with creatinine clearance [CrCl] 15-49 mL/min. Non-recommended doses are prescribed in real-world practice. This analysis of the XANTUS study assessed outcomes associated with non-recommended dosing and patient characteristics that may have impacted dose choice. Methods and results: Baseline characteristics and 1-year outcomes were compared in 4464/6784 patients with known CrCl, receiving recommended or non-recommended rivaroxaban doses; 3608 (80...
November 13, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30398614/long-term-antiarrhythmic-drug-treatment-after-atrial-fibrillation-ablation-does-too-obstinate-rhythm-control-strategy-bring-serious-risk-of-proarrhythmia-to-ablated-patients
#16
Renato De Vecchis
No abstract text is available yet for this article.
November 6, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30339228/corrigendum
#17
(no author information available yet)
No abstract text is available yet for this article.
October 17, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30289484/dropping-aspirin-in-patients-with-atrial-fibrillation-undergoing-percutaneous-coronary-intervention-a-jump-with-a-weak-parachute
#18
Mattia Galli, Felicita Andreotti, Gianluigi Savarese, Domenico D'Amario, Rocco Vergallo, Roberta Della Bona, Leonardo Calò, Italo Porto, Filippo Crea
No abstract text is available yet for this article.
October 5, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30289465/corrigendum
#19
(no author information available yet)
No abstract text is available yet for this article.
October 4, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/30285099/neoatherosclerosis-after-drug-eluting-stent-implantation-a-novel-clinical-and-therapeutic-challenge
#20
Josip A Borovac, Domenico D'Amario, Rocco Vergallo, Italo Porto, Antonio Bisignani, Mattia Galli, Gianmarco Annibali, Rocco A Montone, Antonio Maria Leone, Giampaolo Niccoli, Filippo Crea
The recognition that obstructive disease of the epicardial coronary arteries, causing ischemic heart disease, can be treated with a percutaneous coronary intervention (PCI) has been a major discovery in cardiology in the last 40 years contributing, in particular, to the reduction of mortality associated to acute myocardial infarction (AMI). However, even in the era of drug-eluting stent (DES) implantation, a sizable proportion of patients who undergo PCI may develop late or very late post-implantation complications, that occur in the form of restenosis, neoatherosclerosis and/or in-stent thrombosis...
October 4, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
journal
journal
53372
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"